Nystagmus Market Share And Application By Type (Infantile, Latent Nystagmus, Noonan Syndrome, Nystagmus Blockage Syndrome) Diagnosis (Ct Scan, Mr Scan, Chromosome Analysis, Ultrasonography) Treatment (Medication, Surgical) End-User-Forecast Till 2032

Nystagmus Market Overview

The Nystagmus Market is expected to reach USD 3.3 Billion by 2032 at 7.7% CAGR during the forecast period 2023-2032. Nystagmus is a vision-related medical disease characterized by uncontrolled and repeated eye movements. These motions frequently result in blurred vision, which may wreak havoc on the body's balance and coordination. The prognosis of nystagmus is worsened by fatigue and stress. The specific source of the disease, however, is yet unknown. Congenital neurological problems or neurological abnormalities developing in childhood are the most common causes of nystagmus.

Nystagmus can also be caused by a lack of normal eye movement in childhood, refractive errors such as near-sightedness (myopia) or astigmatism, inflammation of the inner ear, medicines such as anti-epilepsy treatments, and central nervous system illnesses. The rising frequency of genetic and eye-related illnesses is driving the expansion of the nystagmus industry. Furthermore, the market will grow as mental retardation and neurological disorders become more prevalent.

Global Nystagmus Market, by region 2016(%)

Segmentation:

The nystagmus market is segmented on the basis of type, diagnosis, treatment, and end-users.

Based on the type, the market is segmented into infantile, latent nystagmus, noonan syndrome, and nystagmus blockage syndrome.

On the basis of the diagnosis, the market is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others.

On the basis of the treatment, the market is segmented into medications, surgical, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, research centers, specialty eye clinics, and others.

Regional Analysis:

The global nystagmus market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominate the global nystagmus market owing to well-developed technology, increasing number of patients with LASIK eye-related problems, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies in the region have fuelled the growth of the market in this region.  

Europe holds the second position in the global nystagmus market owing to the government support for research & development and availability of funds for research. Moreover, this is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing their investments in the healthcare domain.     

Asia Pacific is the fastest growing nystagmus market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods for eye diseases in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, growing demand for quality devices in the healthcare sector is projected to lead the use of advanced equipment, which, in turn, will increase the market growth of nystagmus in the region.  

On the other hand, in the Middle East and Africa, eye problems have become a huge issue due to limited screening, ignorance of diseases, and poor access to treatment.

Key Players:

Some of key the players in the global nystagmus market are Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others.

Recent Development

Regeneron Pharmaceuticals, Inc. is a biotechnology business that specializes in drug research, development, manufacturing, and commercialization. EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP are among the company's product lines. The company's own VelociSuite technologies, such as VelocImmune, which employs genetically humanized mice to manufacture optimized totally human and bispecific antibodies, help to speed up the traditional drug development process.

Bristol-Myers Squibb is a biopharmaceutical corporation. Biopharmaceutical products are discovered, developed, licensed, manufactured, marketed, distributed, and sold by the company. Oncology, immunology, cardiovascular disease, and fibrosis are among the therapeutic classes for which the company produces pharmaceuticals. Chemically manufactured or tiny molecule medications, as well as biologics created through biological processes, are among the company's pharmaceutical goods. Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude, and Breyanzi are some of the company's products. Wholesalers, distributors, pharmacies, merchants, hospitals, clinics, and government organizations are all customers of its goods.

Intended Audience:

• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Medical Research Laboratories


• Academic Medical Institutes and Universities